INTRODUCTION AND OBJECTIVES: Voltage-dependent anion channel (VDAC), a channel protein, exists in the outer mitochondrial membrane of somatic cells and is involved in multiple physiological and pathophysiological processes. Up until now, little has been known about VDAC in male germ cells. In the present study, the relationship between VDAC and human sperm motility was explored.
METHODS: Highly motile human spermatozoa were incubated in vitro with anti-VDAC antibody. Total sperm motility, straight line velocity (VSL), curvilinear velocity (VCL), and average path velocity (VAP) were recorded. Intracellular free calcium concentration ([Ca2þ]i), pH value (pHi), and ATP content were determined.
RESULTS: Co-incubation with anti-VDAC antibody reduced VSL, VCL, and VAP of spermatozoa. Co-incubation further reduced [Ca2þ]i. Anti-VDAC antibody did not significantly alter total sperm motility, pHi and intracellular ATP content.
CONCLUSIONS: The data suggest that co-incubation with anti-VDAC antibody reduces sperm motility through inhibition of Ca2þ transmembrane flow. In this way, VDAC participates in the modulation of human sperm motility through mediating Ca2þ transmembrane transport and exchange. Panagiota Tsounapi*, Masashi Honda, Yonago, Japan; Fotios Dimitriadis, Ioannina, Greece; Yusuke Kimura, Yonago, Japan; Shogo Shimizu, Nankoku, Japan; Bunya Kawamoto, Katsuya Hikita, Yonago, Japan; Motoaki Saito, Nankoku, Japan; Nikolaos Sofikitis, Ioannina, Greece; Atsushi Takenaka, Yonago, Japan INTRODUCTION AND OBJECTIVES: Epidemiological data indicate that up to 13% of infertility is attributed to cigarette smoking. Nicotine is the most abundant alkaloid chemical in tobacco. We selected nicotine as a major addictive substance of tobacco and investigated its the effects in oxidative stress (OS) changes in epididymis and testis. Additionally we examined if abstinence from nicotine can reverse these changes.
METHODS: Eight-week-old Wistar rats were exposed to oral administration of nicotine (15 mg/kg). One group was exposed to nicotine for 10 weeks (Nico-group) and another group was exposed to nicotine for 7 weeks followed by 3 weeks of abstinence (Abst-group). Control animals had access to fresh water. Tissue levels of malondialdehyde (MDA) and total antioxidant capacity (TAC) were evaluated both in the testis and the epididymis. Additionally, cotinine levels in the urine, serum and seminal vesicular fluid (SVF) were evaluated. Furthermore, testosterone was measured in the urine samples. Finally, immunohistochemistry was performed for OS-markers and Cytochrome P450 2A6 (CYP2A6) in epididymal tail samples.
RESULTS: Nicotine treatment induced significant increases of MDA levels both in the testis and epididymis in Nico-group compared to Abst and Control groups. TAC was significantly lower in both epididymis and testis in Nico group compared to Abst and Control groups. Cotinine levels in urine, serum and SVF were significantly increased in Nicogroup compared to Abst group. Control samples were negative for cotinine. Urine testosterone levels in Nico group were significantly lower compared to Control-group, while there was no significant difference between Control and Abst-group, neither between Nico and Abst groups. Immunohistochemistry revealed mildly stronger intensity for all OS-markers in Nico-group compared with Abst and Control groups. CYP2A6 which is the primary enzyme responsible for the oxidation of nicotine and cotinine was expressed and localized in the epithelial cells of the epididymis in Nico-group.
CONCLUSIONS: Our data demonstrate that the harmful effects of nicotine in the testis and epididymis can be reversed by abstinence. Probably treatment with an antioxidant reagent could enhance the antioxidant defenses of testis and epididymis, and further ameliorate the cigarette smoke-induced oxidative stress in both testicular and epididymal tissue. The present data can provide a helpful tool for clinicians to advice smokers, especially those who attend assisted-reproductive programs, to quit smoking.
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INTRODUCTION AND OBJECTIVES:
The use of cryopreserved of sperm cells from human and animal semen has been a described technique since the 1950s. However, the actual utilization of available cryopreservation technology for human reproduction in sexually intimate partners has been infrequently reported. We set out to examine the utilization of cryopreserved lots of sperm cells processed for males seeking this service at a multispecialty clinic in central Texas during the interval from 1988 through 2015.
METHODS: A retrospective chart review was undertaken of all the cryopreserved semen samples at our institution from the time period specified above. The purpose for cryopreservation and eventual utilization of the sample were recorded along with outcomes of use for insemination. The types of utilization were accumulated as proportions for different purposes. The timing for use for insemination procedures was evaluated using survival statistics. The frequency of patients arranging to destroy samples was also reported.
RESULTS: A total of 1361 cryopreserved semen samples and 81 testicular or epididymal tissue samples were identified. Samples were cryopreserved for 4 purposes: planned intrauterine insemination (IUI), planned in vitro fertilization/intracellular injection (IVF/ICSI), fertility preservation related to cancer treatment, or prior to military deployment. See table 1. Samples cryopreserved for IUI were more likely to be used, whereas VF/ICSI samples were more likely to be destroyed. Of note, while accounting for only a small amount of the samples, those collected for deployment were more likely to be utilized, while those collected for cancer were the least likely to be used. See table 1 for utilization detail. The longest duration from cryopreservation until use was 9.6 years in the cancer cohort. The deployment samples were typically used the earliest. IVF/ICSI samples had the highest proportion of pregnancies (35%).
CONCLUSIONS: The overall utilization rate of cryopreserved samples in our patients was low (mean, 19.3%). Not previously reported, to our knowledge, was that deployment related samples were used second only to IUI and that usage was earlier compared to other than storage indications. Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e87
